Studies of synergistic and antagonistic combinations of conventional cytotoxic agents with the multiple eicosanoid pathway modulator LY 293111

Anti-Cancer Drugs

Volumn 15, Issue 9, 2004, Pages 877-881

  Budman, Daniel R ^a   Calabro, Anthony ^a  

^a NORTH SHORE UNIVERSITY HOSPITAL   (United States)

Author keywords

LY 293111; Median effect; SN 38; Synergy

Indexed keywords

2 [2 PROPYL 3 [3 [2 ETHYL 4 (4 FLUOROPHENYL) 5 HYDROXYPHENOXY]PROPOXY]PHENOXY]BENZOIC ACID; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CISPLATIN; DOXIFLURIDINE; GEMCITABINE;

ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; HUMAN CELL; IC 50; INCUBATION TIME; PRIORITY JOURNAL; SARCOMA CELL;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZOIC ACIDS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; GROWTH INHIBITORS; HUMANS; RECEPTORS, EICOSANOID; SIGNAL TRANSDUCTION;

EID: 8344281385     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200410000-00008     Document Type: Article

References (35)

1. Budman DR, Calabro A, Kreis W. In vitro evaluation of synergism or antagonism with combinations of new cytotoxic agents. Anticancer Drugs 1998; 9:697-702.
2. Adjei AA, Budihardjo II, Rowinsky EK, Kottke TJ, Svingen PA, Buckwalter CA, et al. Cytotoxic synergy between pyrazoloacridine (NSC 366140) and cisplatin in vitro:inhibition of platinum-DNA adduct removal. Clin Cancer Res 1997; 3:761-770.
3. Kahan BD, Gibbons S, Tejpal N, Chou TC, Stepkowski S. Synergistic effect of the rapamycin-cyclosporine combination: median effect analysis of in vitro immune performances by human T lymphocytes in PHA, CD3, and MLR proliferative and cytotoxicity assays. Transplant Proc 1991; 23:1090-1091.
4. Budman DR, Calabro A, Wang LG, Liu XM, Stiel L, Adams LM, et al. Synergism of cytotoxic effects of vinorelbine and paclitaxel in vitro. Cancer Invest 2000; 18:695-701
5. Budman DR, Calabro A, Kreis W. In vitro effects of dexrazoxane (Zinecard) and classical acute leukemia therapy: time to consider expanded clinical trials? Leukemia 2001; 15:1517-1520.
6. Chou TC, Tan QH, Sirotnak FM. Quantitation of the synergistic interaction of edatrexate and cisplatin in vitro. Cancer Chemother Pharmacol 1993; 31:259-264
7. Chou TC, Motzer RJ, Tong Y, Bosl GJ. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst 1994; 86:1517-1524.
8. Kreis W, Budman DR, Calabro A. Synergistic and antagonistic combinations of drugs in human prostate cancer cell lines in vitro. Br J Urol 1997; 79:196-202
9. Budman DR, Calabro A, Kreis W. In vitro search for synergy and antagonism: evaluation of docetaxel combinations in breast cancer cell lines. Breast Cancer Res Treat 2002; 74:41-46
10. Burstein HJ, Kuter I, Campos SM, Gelman RS, Tribou L, Parker LM, et al. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 2001; 19: 2722-2730
11. Budman DR. New directions with capecitabine combinations in advanced breast cancer. Oncology 2002; 16:23-28
12. Yokomizo T, Izumi T, Shimizu T. Leukotriene B4: metabolism and signal transduction. Arch Biochem Biophys 2001; 385:231-214
13. Cristiana B, Hanif R, Kashfi K. The effect of leukotriene B4 and selected HETEs on the proliferation of colon cancer cells. Biochim Biophys Acta 1996; 1300:240-246
14. Earashi M, Noguchi M, Tanaka M. In vitro effects of eicosaniod synthesis inhibitors in the presence of linoleic acid on MDA-MB-231 human breast cancer cells. Breast Cancer Res Treat 1996; 37:29-37
15. Okano M, Ikai K, Imamura S. Human melanoma cells generate leukotriene B4 and C4 from leukotriene A4. Arch Dermatol Res 1997; 289:347-351
16. Tong WG, Ding XZ, Hennig R, Witt RC, Standop J, Pour PM, et al. Leukotriene B4 receptor antagonist LY 293111 inhibits proliferation and induces apoptosis in human pancreatic cancer cells. Clin Cancer Res 2002; 8:3232-3242
17. Perkins E, Cramer J, Farid N, Gadberry M, Jackson D, Mattiuz E, et al. Preclinical characterization of 2-[3-[3-[5-ethyl-4′-fluoro-2-hydroxy[1, 1′-biphenyl]-4-yl]oxy]propoxy]-2-propylphenoxy]benzoic acid metabolism: in vitro species comparison and in vivo disposition in rats. Drug Metab Disp 2003; 31:1382-1390
18. Kuwabara K, Yasui K, Jyoyama H, Maruyama T, Fleisch JH, Hori Y. Effects of the second-generation leukotriene B(4) receptor antagonist, LY 293111Na, on leukocyte infiltration and collagen-induced arthritis in mice. Eur J Pharmacol 2000; 402:275-285
19. Marder P, Sawyer JS, Froelich LL, Mann LL, Spaethe SM. Blockade of human neutrophil activation by 2-[2-propyl-3-[3-[2-ethyl-4-(4-fluorophenyl)-5- hydroxyphenoxy]propoxy]phenoxy]benzoic acid (LY 293111), a novel leukotriene B4 receptor antagonist. Biochem Pharmacol 1995; 49: 1683-1690
20. Schwartz G, Budman D, Endres S, Welch M, O'Reilly E, Barile-Thiem B, et al. Phase I and pharmacokinetic study of LY 293111, an orally available small molecule known to be an LTB4 receptor antagonist, 5-lipoxygenase inhibitor, and peroxisome proliferator activated receptor gamma agonist. Proc Am Soc Clin Oncol 2002; 21:343a
21. Chou T, Talalay P. Generalized equations for the analysis of inhibitions of Michaelis-Menton and higher order kinetic systems with two or more mutually exclusive and non-exclusive inhibitors. Eur J Biochem 1988; 115:207-216
22. Adams J. Potential for proteasome inhibition in the treatment of cancer. Drug Disc Today 2003; 7:307-315
23. Gabriel B, Fischer DC, Kieback DG. Molecular mechanisms in signal transduction:new targets for the therapy of gynecologic malignancies. Onkologie 2002; 25:240-247
24. Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 2001; 93:1852-1857
25. Moasser MM, Basso A, Averbuch SD, Rosen N. The tyrosine kinase inhibitor ZD1839 ('Iressa') inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res 2001; 61: 7184-7188
26. Nagy P, Jenei A, Damjanovich S, Jovin TM, Szolosi J. Complexity of signal transduction mediated by ErbB2: clues to the potential of receptor-targeted cancer therapy. Pathol Oncol Res 1999; 5:255-271
27. Sinha S, Corey SJ. Implications for Src kinases in hematopoiesis: signal transduction therapeutics. J Hematother Stem Cell Res 1999; 8:465-480
28. Ding XZ, Hennig R, Adrian TE. Lipoxygenase and cyclooxygenase metabolism: new insights in treatment and chemoprevention of pancreatic cancer. Mol Cancer 2003; 2:10
29. Gupta RA, Tejada LV, Tong BJ, Das SK, Morrow JD, Dey SK, et al. Cyclooxygenase-1 is overexpressed and promotes angiogenic growth factor production in ovarian cancer. Cancer Res 2003; 63:906-911
30. Singh B, Lucci A. Role of cyclooxygenase-2 in breast cancer. J Surg Res 2002; 108:173-179
31. Stoehlmacher J, Lenz HJ. Cyclooxygenase-2 inhibitors in colorectal cancer. Semin Oncol 2003; 30:10-16
32. Altorki N, Keresztes R, Port J, Libby D, Korst R, Flieder D, et al. Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer. J Clin Oncol 2003; 21:2645-2650
33. Subbaranaiah K, Derrick T, Hart J, Dannenberg A. Peroxisome proliferator-activated receptor gamma ligands suppress the transcriptional activation of cyclooxygenase-2. J Biol Chem 2001; 276:12440-12448
34. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998; 391:79-82
35. Inoue H, Tanabe T, Umesono K. Feedback control of cyclooxygenase-2 expression through PPAR-gamma. J Biol Chem 2000; 275:28028-28032.